Research & Development: Page 2
-
Stock via Getty Images
After myriad failures, a new wave of ALS drugs approaches
Several drugmakers anticipate trial results and FDA submissions in 2025 and 2026, including some still overcoming past failures.
By Amy Baxter • June 25, 2025 -
Permission granted by Parabilis
Q&AHow a Big Pharma veteran looks to stand out in biotech as a unique ‘drug hunter’
J&J’s former head of R&D, now CEO of Parabilis Medicines, aims to remain above the biotech fray by taking on unique targets from which others have steered clear.
By Michael Gibney • June 24, 2025 -
Explore the Trendline➔
Stock via Getty Images
TrendlineRare diseases
As drug developers find promise in the rare diseases, deals and treatments are on the rise
By PharmaVoice staff -
iStock via Getty Images
Biotech’s turning point: for every challenge, an opportunity in disguise
As hurdles litter biotech’s future, forward-thinking leaders look for ways to leap to the other side.
By Michael Gibney • June 20, 2025 -
Permission granted by Novartis
ProfileThe former Wall Street analyst shaping Novartis’ big-picture strategy
Ronny Gal, chief strategy and growth officer at Novartis, is guiding the company into a new era shaped by science-minded M&A and a slimmed-down pivot.
By Michael Gibney • June 10, 2025 -
Permission granted by Pfizer
Sponsored by PfizerThe mindfulness of medicine development: How scientists are driving the next wave of medical innovations
For millions of patients, the development of a new treatment or vaccine can be life-changing.
June 9, 2025 -
Permission granted by Daiichi Sankyo
With ADCs on the rise, drugmakers embrace a new oncology pillar
A slow ascent for more than two decades has given way to a sharp rise in important ADC readouts, marking a milestone era for targeted treatments.
By Michael Gibney • June 6, 2025 -
BrasilNut1 via Getty Images
How leading oncology drugmakers set the stage for future advances
Drugmakers like J&J and Astellas are looking beyond today’s cancer treatments for the windows of opportunity decades down the road.
By Michael Gibney • June 3, 2025 -
Thomas Lohnes via Getty Images
COVID’s remaining biotech contenders navigate a dwindling market
With policy and funding evolving, companies are being forced to rethink strategies.
By Kelly Bilodeau • June 2, 2025 -
Courtesy of AbbVie
AbbVie’s ADC win shows how pharma can break through in solid tumors
An oncology pivot recently paid off for the large pharma, which scored a milestone nod for its lead ADC.
By Meagan Parrish • May 30, 2025 -
Scott Olson via Getty Images
Lilly to buy pain drug developer SiteOne, challenging Vertex
The acquisition expands Lilly’s pain pipeline with a slate of drugs targeting ion channel proteins like NaV1.7 and NaV1.8.
By Jacob Bell • May 28, 2025 -
iStock via Getty Images
With new Alzheimer’s blood test cleared, a potential vaccine could be on the horizon
Nuravax and others are working on the next wave of Alzheimer’s treatments to catch the disease before symptoms arise.
By Michael Gibney • May 28, 2025 -
Permission granted by Zealand Pharma
Q&A // First 90 DaysLilly’s former small molecule head makes the leap to a rising biotech in obesity
Utpal Singh joined the peptide-focused biotech Zealand Pharma last month after it notched a massive obesity deal with Roche.
By Amy Baxter • May 21, 2025 -
Justin Sullivan via Getty Images
Regeneron wins bid to buy 23andMe out of bankruptcy
The biotech, which has for years invested in genetics research, plans to acquire "substantially all" of testing firm 23andMe's assets for $256 million.
By Ned Pagliarulo • May 20, 2025 -
Stock via Getty Images
The placebo effect: How a new FDA rule could pile more strain onto vaccine developers
The proposed plan would require placebo testing for all new vaccines and could mean additional costs and time for R&D.
By Alexandra Pecci • May 20, 2025 -
Philip Pacheco via Getty Images
A startup with Theranos ties has another blood test in the works. This time, competition is waiting.
A stealth startup built by the partner of disgraced Theranos founder Elizabeth Holmes is taking a shot at a new blood test — an area where other companies are already making strides.
By Meagan Parrish • May 16, 2025 -
Permission granted by Editas
Q&A // First 90 DaysA new CFO tasked with taking ‘scrappy’ Editas from last year’s layoffs into new gene editing territory
Amy Parison, who stepped into the lead financial role at the company in March, is managing Editas Medicine’s transition to a new gene editing platform while recovering from a major overhaul.
By Michael Gibney • May 15, 2025 -
FatCamera via Getty Images
Women’s health faces growing headwinds, despite jump in venture investment
While venture funding is rising, federal policy upheaval may affect women’s health research more acutely than other fields, one biotech CEO said.
By Delilah Alvarado • May 14, 2025 -
Sedat Suna via Getty Images
Lupus R&D has come a long way, and the next breakthroughs could come from cell therapy
But the therapies will need to prove their worth in the clinic over the next few years.
By Kelly Bilodeau • May 12, 2025 -
Stock via Getty Images
AI is already delivering pharma value — and not just in drug discovery
While AI-generated drugs grab headlines, the technology is making more of an impact doing less “glamorous” tasks.
By Meagan Parrish • May 12, 2025 -
Michael M. Santiago via Getty Images
RFK Jr.’s autism fixation hearkens back to his stance on vaccines
The head of HHS is seeking the “root causes” of autism spectrum disorder through a large government research project.
By Amy Baxter • May 9, 2025 -
Jacob Bell/PharmaVoice
Alnylam keeps pushing the rare disease paradigm as RNAi promises even wider indications
With another rare disease approval under its belt, Alnylam is still revving up the R&D engines for new indications.
By Michael Gibney • May 8, 2025 -
Stock via Getty Images
Prasad’s FDA appointment pressures cell and gene therapy stocks
A vocal opponent of his predecessor Peter Marks, Dr. Vinay Prasad will now lead the office tasked with reviewing some genetic medicines, adding more uncertainty to an already struggling field of research.
By Ben Fidler • May 7, 2025 -
Stock via Getty Images
After an up and down year, pharma’s R&D landscape is shifting again
While clinical trial funding was up, deal-making was down, and new uncertainties are coming into the picture.
By Kelly Bilodeau • May 5, 2025 -
Spencer Platt via Getty Images
With compounders out of the way, Lilly and Novo go after each other
The two obesity leaders are pulling on all levers to stay on top of the market.
By Amy Baxter • May 5, 2025 -
Stock via Getty Images
Is pharma ready to let go of animal testing?
Regulators have signaled their willingness to embrace alternative tests and guide the industry in new directions.
By Meagan Parrish • May 2, 2025
Previous
